First-in-Human phase 1 study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solidtumors

Presented at ESMO 2020

H. Gelderblom¹, J. Gietema², I. Desar³, N. Ajmone⁴, M. Jalving², J. Kroep¹, V. Nicolas⁵, A. Vaslin⁵, K. Tobal⁵, D. Purcea⁵, S. van Haren⁵, L. Damstrup⁵

1. Medical Oncology Dept, Leiden University Medical Center (LUMC), Leiden, The Netherlands,
2. Department of Medical Oncology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands,
3. Department of Medical Oncology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands,
4. Cardiology, Department, LUMC, Leiden, The Netherlands,
5. Debiopharm International S.A., Lausanne, Switzerland